Evidence map›Paper›PMID 38508183›Full record

ArticleMolecular cell2024

FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis.

Joel William Francis, Simone Hausmann, Sabeen Ikram, Kunlun Yin, Robert Mealey-Farr, Natasha Mahealani Flores, Annie Truc Trinh, Tourkian Chasan, Julia Thompson, Pawel Karol Mazur and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. SVC112: From Hummingbirds to Head and Neck Cancer.Advances in experimental medicine and biology · 2025
    Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Joel William FrancisDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Simone HausmannDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sabeen IkramDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Kunlun YinDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert Mealey-FarrDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Natasha Mahealani FloresDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Annie Truc TrinhDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Tourkian ChasanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Julia ThompsonDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pawel Karol MazurDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: pkmazur@mdanderson.org.
Or GozaniDepartment of Biology, Stanford University, Stanford, CA 94305, USA. Electronic address: ogozani@stanford.edu.
The University of Texas MD Anderson Cancer Center · USStanford University · USStanford Medicine · US

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Function of Protein Methylation in Chromatin and Signaling RegulationR35GM139569 · NIGMS · STANFORD UNIVERSITY · PI Or P. Gozani · 2021 to 2026
$4.0M
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2M
Therapeutic Targeting of NSD2 in Lung AdenocarcinomaR01CA272844 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6M
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancerR01CA272843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD, Pawel K. Mazur · 2023 to 2026
$2.6M
Role of NSD3 in regulation of cancer pathogenesisR01CA278940 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6M
Role of the METTL13 Lysine Methyltransferase in Signaling and CancerR01CA236118 · NCI · STANFORD UNIVERSITY · PI GOZANI, OR P., MAZUR, PAWEL K. · 2019 to 2023
$2.4M
Role of SETD5 in Chromatin Regulation and TumorigenesisR01CA236949 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2019 to 2023
$1.9M
Mechanisms of translational output control in pancreatic cancerK99CA255936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAUSMANN, SIMONE CHRISTINE · 2021 to 2022
$224k
Role of the candidate protein methyltransferase METTL18 in cancer biologyF31CA261128 · NCI · STANFORD UNIVERSITY · PI FRANCIS, JOEL · 2022 to 2023
$70k
NCI NIH HHS F31 CA261128NCI NIH HHS K99 CA255936NCI NIH HHS R01 CA236118NCI NIH HHS R01 CA236949NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA272843NCI NIH HHS R01 CA272844NCI NIH HHS R01 CA278940NIGMS NIH HHS R35 GM139569NIGMS NIH HHS T32 GM007276
6 · The paper itself

Abstract

eEF2 post-translational modifications (PTMs) can profoundly affect mRNA translation dynamics. However, the physiologic function of eEF2K525 trimethylation (eEF2K525me3), a PTM catalyzed by the enzyme FAM86A, is unknown. Here, we find that FAM86A methylation of eEF2 regulates nascent elongation to promote protein synthesis and lung adenocarcinoma (LUAD) pathogenesis. The principal physiologic substrate of FAM86A is eEF2, with K525me3 modeled to facilitate productive eEF2-ribosome engagement during translocation. FAM86A depletion in LUAD cells causes 80S monosome accumulation and mRNA translation inhibition. FAM86A is overexpressed in LUAD and eEF2K525me3 levels increase through advancing LUAD disease stages. FAM86A knockdown attenuates LUAD cell proliferation and suppression of the FAM86A-eEF2K525me3 axis inhibits cancer cell and patient-derived LUAD xenograft growth in vivo. Finally, FAM86A ablation strongly attenuates tumor growth and extends survival in KRAS

Indexed as

Adenocarcinoma of LungCarcinogenesisLung NeoplasmsPeptide Elongation Factor 2RNA, MessengerAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMethylationMiceMice, NudePeptide Chain Elongation, TranslationalProtein Processing, Post-TranslationalPeptide Elongation Factor 2RNA, MessengercancereEF2elongationFAM86AKRASlunglysine methylationmRNA translationprotein synthesis

Identifiers

PMID38508183
PMCPMC11069438
OpenAlexW4392951096

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.